APD403 Demonstrates Control of Nausea and Vomiting after Highly Emetogenic Chemotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A phase II study of APD403 in the prevention of chemotherapy-induced nausea and vomiting reported positive results in patients receiving highly emetogenic chemotherapy—either high-dose cisplatin, or cyclophosphamide and an anthracycline for breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login